Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) represents a critical complication of Diabetes mellitus (DM), characterized by structural and functional changes in the myocardium independent of coronary artery disease or hypertension. Emerging evidence highlights the significant roles of phytochemicals, particularly...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024160276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166986600480768 |
|---|---|
| author | Sachin Dhiman Sanchit Dhankhar Anjali Garg Manni Rohilla Monika Saini Thakur Gurjeet Singh Samrat Chauhan Samy Selim Soad K. Al Jaouni Sabina Yasmin Naseem Begum Aziza Alshahrani Mohammad Yousuf Ansari |
| author_facet | Sachin Dhiman Sanchit Dhankhar Anjali Garg Manni Rohilla Monika Saini Thakur Gurjeet Singh Samrat Chauhan Samy Selim Soad K. Al Jaouni Sabina Yasmin Naseem Begum Aziza Alshahrani Mohammad Yousuf Ansari |
| author_sort | Sachin Dhiman |
| collection | DOAJ |
| description | Diabetic cardiomyopathy (DCM) represents a critical complication of Diabetes mellitus (DM), characterized by structural and functional changes in the myocardium independent of coronary artery disease or hypertension. Emerging evidence highlights the significant roles of phytochemicals, particularly astilbin and apigenin, in modulating key molecular pathways implicated in DCM. This review synthesizes current mechanistic insights and therapeutic potential of these compounds, focusing on their interactions with AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptors (PPARs), O-linked N-acetylglucosamine (O-GlcNAc), sodium-glucose co-transporter 2 (SGLT2), protein kinase C (PKC), nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) pathways. Astilbin and apigenin have demonstrated the ability to improve cardiac function, mitigate oxidative stress, and reduce inflammatory responses in diabetic conditions. By activating AMPK and PPARs, these flavonoids enhance glucose uptake and fatty acid oxidation, contributing to improved metabolic homeostasis. Their inhibition of O-GlcNAcylation, SGLT2 activity, and PKC signaling further attenuates hyperglycemia-induced cellular damage. Additionally, suppression of NF-κB, MAPK, and JNK pathways by astilbin and apigenin results in reduced pro-inflammatory cytokine production and apoptotic cell death. Collectively, these interactions position astilbin and apigenin as promising therapeutic agents for ameliorating DCM, offering novel avenues for treatment strategies aimed at modulating multiple pathogenic pathways. |
| format | Article |
| id | doaj-art-a2cf99bf1e46465e8a92b9884a08cb0a |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-a2cf99bf1e46465e8a92b9884a08cb0a2024-11-15T06:14:10ZengElsevierHeliyon2405-84402024-11-011021e39996Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathySachin Dhiman0Sanchit Dhankhar1Anjali Garg2Manni Rohilla3Monika Saini4Thakur Gurjeet Singh5Samrat Chauhan6Samy Selim7Soad K. Al Jaouni8Sabina Yasmin9Naseem Begum10Aziza Alshahrani11Mohammad Yousuf Ansari12Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India; Swami Devi Dyal College of Pharmacy, GolpuraBarwala, Panchkula, Haryana, 134118, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India; Swami Vivekanand College of Pharmacy, Ram Nagar, Banur, Punjab, 140601, IndiaSwami Vivekanand College of Pharmacy, Ram Nagar, Banur, Punjab, 140601, India; M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, 133206, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India; Corresponding author.Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, 72388, Saudi ArabiaDepartment of Hematology/Oncology, Yousef Abdulatif Jameel Scientific Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi ArabiaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, 62529, Saudi ArabiaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 62529, Saudi ArabiaDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, 62529, Saudi ArabiaM.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, 133206, India; Corresponding author. MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, 133207, India.Diabetic cardiomyopathy (DCM) represents a critical complication of Diabetes mellitus (DM), characterized by structural and functional changes in the myocardium independent of coronary artery disease or hypertension. Emerging evidence highlights the significant roles of phytochemicals, particularly astilbin and apigenin, in modulating key molecular pathways implicated in DCM. This review synthesizes current mechanistic insights and therapeutic potential of these compounds, focusing on their interactions with AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptors (PPARs), O-linked N-acetylglucosamine (O-GlcNAc), sodium-glucose co-transporter 2 (SGLT2), protein kinase C (PKC), nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) pathways. Astilbin and apigenin have demonstrated the ability to improve cardiac function, mitigate oxidative stress, and reduce inflammatory responses in diabetic conditions. By activating AMPK and PPARs, these flavonoids enhance glucose uptake and fatty acid oxidation, contributing to improved metabolic homeostasis. Their inhibition of O-GlcNAcylation, SGLT2 activity, and PKC signaling further attenuates hyperglycemia-induced cellular damage. Additionally, suppression of NF-κB, MAPK, and JNK pathways by astilbin and apigenin results in reduced pro-inflammatory cytokine production and apoptotic cell death. Collectively, these interactions position astilbin and apigenin as promising therapeutic agents for ameliorating DCM, offering novel avenues for treatment strategies aimed at modulating multiple pathogenic pathways.http://www.sciencedirect.com/science/article/pii/S2405844024160276ApigeninAstilbinDiabetesCardiomyopathy |
| spellingShingle | Sachin Dhiman Sanchit Dhankhar Anjali Garg Manni Rohilla Monika Saini Thakur Gurjeet Singh Samrat Chauhan Samy Selim Soad K. Al Jaouni Sabina Yasmin Naseem Begum Aziza Alshahrani Mohammad Yousuf Ansari Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy Heliyon Apigenin Astilbin Diabetes Cardiomyopathy |
| title | Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| title_full | Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| title_fullStr | Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| title_full_unstemmed | Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| title_short | Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| title_sort | mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy |
| topic | Apigenin Astilbin Diabetes Cardiomyopathy |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024160276 |
| work_keys_str_mv | AT sachindhiman mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT sanchitdhankhar mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT anjaligarg mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT mannirohilla mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT monikasaini mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT thakurgurjeetsingh mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT samratchauhan mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT samyselim mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT soadkaljaouni mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT sabinayasmin mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT naseembegum mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT azizaalshahrani mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy AT mohammadyousufansari mechanisticinsightsandtherapeuticpotentialofastilbinandapigeninindiabeticcardiomyopathy |